CLLS Cellectis

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLLS

Price (delayed)

$2.99

Market cap

$214.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.77

Enterprise value

$183.69M

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene ...

Highlights
CLLS's equity is down by 28% year-on-year but it is up by 11% since the previous quarter
The company's EPS rose by 24% YoY but it fell by 7% QoQ
The company's gross profit has shrunk by 65% YoY and by 64% QoQ
The revenue has plunged by 64% YoY and by 63% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cellectis.com
Peers: QURE NVAX REGN

Key stats

What are the main financial stats of CLLS
Market
Shares outstanding
71.75M
Market cap
$214.54M
Enterprise value
$183.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.96
Price to sales (P/S)
18.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.98
Earnings
Revenue
$9.19M
EBIT
-$60.05M
EBITDA
-$41.52M
Free cash flow
-$25.82M
Per share
EPS
-$1.77
Free cash flow per share
-$0.45
Book value per share
$1.52
Revenue per share
$0.16
TBVPS
$5.85
Balance sheet
Total assets
$334.27M
Total liabilities
$249.58M
Debt
$105.86M
Equity
$84.7M
Working capital
$77.86M
Liquidity
Debt to equity
1.25
Current ratio
1.5
Quick ratio
1.45
Net debt/EBITDA
0.74
Margins
EBITDA margin
-451.7%
Gross margin
92%
Net margin
-1,099.3%
Operating margin
-1,058.4%
Efficiency
Return on assets
-39.5%
Return on equity
-108.9%
Return on invested capital
-32%
Return on capital employed
-33.5%
Return on sales
-653.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLLS stock price

How has the Cellectis stock price performed over time
Intraday
0%
1 week
20.56%
1 month
7.17%
1 year
60.75%
YTD
-2.92%
QTD
12.83%

Financial performance

How have Cellectis's revenue and profit performed over time
Revenue
$9.19M
Gross profit
$8.46M
Operating income
-$97.3M
Net income
-$101.06M
Gross margin
92%
Net margin
-1,099.3%
The company's net margin has shrunk by 166% YoY
The company's gross profit has shrunk by 65% YoY and by 64% QoQ
The revenue has plunged by 64% YoY and by 63% from the previous quarter
The company's operating income fell by 32% QoQ and by 9% YoY

Growth

What is Cellectis's growth rate over time

Valuation

What is Cellectis stock price valuation
P/E
N/A
P/B
1.96
P/S
18.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.98
The company's EPS rose by 24% YoY but it fell by 7% QoQ
The P/B is 51% more than the last 4 quarters average of 1.3 and 9% more than the 5-year quarterly average of 1.8
CLLS's equity is down by 28% year-on-year but it is up by 11% since the previous quarter
The price to sales (P/S) is 144% higher than the last 4 quarters average of 7.6 and 4.7% higher than the 5-year quarterly average of 17.7
The revenue has plunged by 64% YoY and by 63% from the previous quarter

Efficiency

How efficient is Cellectis business performance
The company's return on sales has shrunk by 90% YoY
The return on equity has dropped by 58% year-on-year and by 29% since the previous quarter
CLLS's return on invested capital is down by 36% since the previous quarter but it is up by 17% year-on-year
CLLS's ROA is down by 13% year-on-year and by 10% since the previous quarter

Dividends

What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLLS.

Financial health

How did Cellectis financials performed over time
CLLS's total assets is 34% greater than its total liabilities
Cellectis's total liabilities has soared by 87% from the previous quarter and by 84% YoY
CLLS's total assets has surged by 59% since the previous quarter and by 28% year-on-year
The company's debt is 25% higher than its equity
CLLS's debt to equity has soared by 79% year-on-year but it is down by 5% since the previous quarter
CLLS's equity is down by 28% year-on-year but it is up by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.